Albuterol (Salbutamol)

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Also Known As:

Networked: 3879 relevant articles (490 outcomes, 750 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Beasley, Richard: 19 articles (04/2024 - 06/2003)
2.	Papi, Alberto: 17 articles (04/2024 - 03/2003)
3.	Weatherall, Mark: 12 articles (04/2024 - 06/2003)
4.	Israel, Elliot: 12 articles (01/2024 - 12/2002)
5.	Szefler, Stanley J: 12 articles (08/2016 - 09/2002)
6.	Sorkness, Christine A: 11 articles (08/2016 - 11/2003)
7.	Cazzola, Mario: 10 articles (01/2021 - 01/2004)
8.	Lemanske, Robert F: 10 articles (08/2016 - 11/2003)
9.	Chipps, Bradley E: 9 articles (02/2024 - 04/2006)
10.	Tan, Wen: 9 articles (08/2023 - 02/2014)

Related Diseases

1.	Asthma (Bronchial Asthma) 02/01/2013 - "This study aimed to assess the safety and efficacy of a high-dose continuous nebulized albuterol (CNA) protocol for treatment of asthma in the pediatric emergency department (ED). " 01/01/2022 - "Whether the use of nebulized salbutamol with or without MgSO4 in the management of acute asthma results in clinically significant improvement in lung function in Indian children? " 01/28/2017 - "In children with persistent asthma, albuterol MDPI improved pulmonary function significantly better than placebo MDPI over 3 weeks of treatment. " 02/01/2016 - "In total, 47 patients with asthma (18 males 39 ± 13 years, FEV1 = 79 ± 21%) reported significantly improved FEV1, FEV1/forced vital capacity (FVC), residual volume (RV)/total lung capacity (TLC) (all P = .0001) and VDP (P = .01) post-salbutamol. " 05/01/2014 - "Significant reduction in asthma symptom days, nighttime awakenings, days with activity limitation, and albuterol use were observed. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 11/01/2005 - "Nebulised salbutamol improved forced expiratory flow in most patients with COPD, but less hyper-nflated patients tried to reduce the abdominal compartmental volume after active treatment and this reduced their exercise capacity. " 08/01/2012 - "Forced expiratory volume in 1 s (FEV(1)) increase after salbutamol was similar in SC (mean 0.14 litres (SD 0.15)) and COPD (0.12 litres (0.15)) and was significantly greater than NSC (0.08 litres (0.14)). " 07/01/2005 - "There was significant improvement in Emax to inhaled albuterol as the COPD exacerbation resolved. " 09/01/2003 - "Furthermore, especially in the COPD patients a significant decrease was observed in hyperinflation and consequently an improvement in maximal inspiratory pressure as a result of salbutamol via all devices. " 04/01/2009 - "The use of albuterol improved the resistive and reactive properties of the respiratory system of the COPD patients under study. "
3.	Bronchiolitis 06/01/1998 - "Salbutamol was shown to be effective and safe in the treatment of acute bronchiolitis." 06/01/1994 - "Albuterol is as effective as oral placebo in the management of bronchiolitis. " 01/01/1995 - "Salbutamol is safe and effective in relieving the respiratory distress of young infants with acute bronchiolitis. " 05/01/1991 - "We conclude that salbutamol is safe and effective for the initial treatment of young children with acute bronchiolitis." 10/01/1990 - "We conclude that nebulized albuterol constitutes a safe and effective treatment of infants with bronchiolitis."
4.	Respiratory Sounds (Crackle) 06/01/1996 - "This study demonstrates that oral salbutamol is beneficial in the treatment of acute episodes of wheezing in infancy. " 09/01/2017 - "PACQLQ scores were significantly associated with improved ACT scores (r = .37 to .47, p < .05), fewer days/month of albuterol use (r = -.25 to -.36., p < .05), and wheezing (r = -.28 to -.33, p < .05). " 01/01/1995 - "Patients in the salbutamol group exhibited significantly greater improvement in respiratory rate (P = 0.01), accessory muscle score (P < 0.001) and wheezing score (P < 0.001). " 01/01/1994 - "Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. " 01/01/1992 - "After two nebulizations, the albuterol-treated patients had a greater improvement in clinical status (respiratory rate, degree of wheezing and accessory muscle use, total clinical score, and arterial oxygen saturation) than the placebo group. "
5.	Bronchial Spasm 08/01/1995 - "Albuterol later became the prototype selective beta 2-agonist--well tolerated and highly effective in controlling bronchospasm. " 01/01/2019 - "Desensitization was acutely successful in 22 (92%) patients and unsuccessful in 2 (8%) patients who both had a single short-lived episode of acute bronchospasm treated successfully with nebulized salbutamol. " 11/01/2009 - "Children with a recent RTI who received salbutamol demonstrated a significantly reduced incidence of perioperative bronchospasm (5.5% vs 11%, P = 0.0270) and severe coughing (5.5% vs 11.5%, P = 0.0314) compared with children who had an RTI but did not receive salbutamol. " 11/01/2009 - "salbutamol) is effective in preventing increases in total respiratory resistance and in decreasing the incidence of perioperative bronchospasm in asthmatic children. " 01/01/1978 - "Salbutamol relieved all symptoms of bronchospasm."

Related Drugs and Biologics

1.	Ipratropium (Ipratropium Bromide)
2.	Bronchodilator Agents (Bronchodilators)
3.	Albuterol (Salbutamol)
4.	Formoterol Fumarate (Oxis)
5.	Salmeterol Xinafoate (Serevent)
6.	Epinephrine (Adrenaline)
7.	Theophylline (Theon)
8.	Fluticasone (Cutivate)
9.	Beclomethasone (Beclometasone)
10.	Aerosols

Related Therapies and Procedures

1.	Therapeutics
2.	Nebulizers and Vaporizers (Inhaler)
3.	Metered Dose Inhalers (Metered Dose Inhaler)
4.	Length of Stay
5.	Oral Administration